Clal Biotechnology (Israel) Price Prediction
| CBI Stock | 37.80 1.40 3.85% |
Oversold Vs Overbought
41
Oversold | Overbought |
Using Clal Biotechnology hype-based prediction, you can estimate the value of Clal Biotechnology Industries from the perspective of Clal Biotechnology response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Clal Biotechnology to buy its stock at a price that has no basis in reality. In that case, they are not buying Clal because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Clal Biotechnology after-hype prediction price | ILA 37.8 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Clal |
Clal Biotechnology After-Hype Price Prediction Density Analysis
As far as predicting the price of Clal Biotechnology at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Clal Biotechnology or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Clal Biotechnology, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Clal Biotechnology Estimiated After-Hype Price Volatility
In the context of predicting Clal Biotechnology's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Clal Biotechnology's historical news coverage. Clal Biotechnology's after-hype downside and upside margins for the prediction period are 34.82 and 40.78, respectively. We have considered Clal Biotechnology's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Clal Biotechnology is very steady at this time. Analysis and calculation of next after-hype price of Clal Biotechnology is based on 3 months time horizon.
Clal Biotechnology Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Clal Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Clal Biotechnology backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Clal Biotechnology, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.10 | 2.98 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | In 5 to 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
37.80 | 37.80 | 0.00 |
|
Clal Biotechnology Hype Timeline
Clal Biotechnology is currently traded for 37.80on Tel Aviv Stock Exchange of Israel. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Clal is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at -0.1%. %. The volatility of related hype on Clal Biotechnology is about 0.0%, with the expected price after the next announcement by competition of 37.80. About 65.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.68. Some equities with similar Price to Book (P/B) outperform the market in the long run. Clal Biotechnology recorded a loss per share of 0.57. The entity last dividend was issued on the 29th of March 2021. Assuming the 90 days trading horizon the next forecasted press release will be in 5 to 10 days. Check out Clal Biotechnology Basic Forecasting Models to cross-verify your projections.Clal Biotechnology Related Hype Analysis
Having access to credible news sources related to Clal Biotechnology's direct competition is more important than ever and may enhance your ability to predict Clal Biotechnology's future price movements. Getting to know how Clal Biotechnology's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Clal Biotechnology may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| KMDA | Kamada | 0.00 | 0 per month | 1.66 | (0.06) | 2.89 | (2.84) | 8.52 | |
| BLRX | BioLine RX | 0.00 | 0 per month | 0.00 | (0.22) | 5.51 | (11.73) | 35.24 | |
| EVGN | Evogene | 0.00 | 0 per month | 0.00 | (0.41) | 5.18 | (9.63) | 30.28 | |
| BEZQ | Bezeq Israeli Telecommunication | 0.00 | 0 per month | 1.29 | 0.11 | 3.25 | (2.35) | 8.84 | |
| CGEN | Compugen | 0.00 | 0 per month | 0.00 | (0.09) | 6.50 | (5.99) | 21.13 |
Clal Biotechnology Additional Predictive Modules
Most predictive techniques to examine Clal price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Clal using various technical indicators. When you analyze Clal charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Clal Biotechnology Predictive Indicators
The successful prediction of Clal Biotechnology stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Clal Biotechnology Industries, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Clal Biotechnology based on analysis of Clal Biotechnology hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Clal Biotechnology's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Clal Biotechnology's related companies.
Story Coverage note for Clal Biotechnology
The number of cover stories for Clal Biotechnology depends on current market conditions and Clal Biotechnology's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Clal Biotechnology is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Clal Biotechnology's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Clal Biotechnology Short Properties
Clal Biotechnology's future price predictability will typically decrease when Clal Biotechnology's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Clal Biotechnology Industries often depends not only on the future outlook of the potential Clal Biotechnology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Clal Biotechnology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 161.1 M | |
| Dividends Paid | 36 M | |
| Forward Annual Dividend Rate | 0.22 |
Complementary Tools for Clal Stock analysis
When running Clal Biotechnology's price analysis, check to measure Clal Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clal Biotechnology is operating at the current time. Most of Clal Biotechnology's value examination focuses on studying past and present price action to predict the probability of Clal Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clal Biotechnology's price. Additionally, you may evaluate how the addition of Clal Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stocks Directory Find actively traded stocks across global markets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |